Glaucoma is a blinding
INTRODUCTION
Glaucoma is an eye disorder that is the second leading cause of blindness world-wide after cataract (1) . The most common form of glaucoma is primary open angle glaucoma (POAG). It is characterized by degeneration and cupping of the optic nerve, a characteristic pattern of visual field loss and increased intraocular pressure (IOP) in a majority of cases. The age at diagnosis for POAG ranges from <10 years to >70 years, with a majority of cases occurring after the age of 40. A number of genes have been implicated in the pathogenesis of various forms of glaucoma (2) (3) (4) (5) (6) (7) (8) (9) . Of these genes, only mutations in the gene TIGR/MYOC have been shown to cause a POAG phenotype, accounting for 2-4% of cases (4, (10) (11) (12) (13) . Most mutations in TIGR/MYOC result in dominant early onset POAG, typified by high IOP.
The function(s) of the TIGR/myocilin protein and the mechanism(s) by which mutations in the gene cause glaucoma are not known. The gene was initially named trabecular meshwork-inducible glucocorticoid response (TIGR), on the basis of a high level of induction of mRNA and protein following dexamethasone treatment of human trabecular meshwork (HTM) cells (14) . Kubota et al. (15) independently identified the gene and named it myocilin (MYOC) because sequence analysis revealed similarity to Dictyostelium discoideum myosin and the protein appeared to localize to the connecting cilium of retinal photoreceptor cells. The region of myosin similarity is predicted to form a coiled-coil structure (14, 15) and there is a potential N-terminal signal sequence, consistent with evidence that the protein is secreted from glucocorticoidtreated HTM cells (14) . Most glaucoma-causing mutations affect residues in the C-terminal half of the protein in a putative domain that shares similarity with bullfrog olfactomedin (15, 16) , an extracellular matrix protein of unknown function that is an abundant constituent of the frog olfactory neuroepithelium (17) . Sequence comparisons indicate that the olfactomedin-like domain is phylogenetically conserved to nematodes (18, 19) .
A catalog of mutant forms of TIGR/MYOC may provide clues to the protein's normal function(s) and the mechanism(s) by which mutations cause glaucoma. Extensive screening of TIGR/MYOC in glaucomatous and normal individuals has revealed many missense variants and a handful of premature termination and frameshift mutations (4, (10) (11) (12) (13) 18, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . Some of the missense variants have been shown to co-segregate with a POAG phenotype in families with many affected members, providing statistical evidence for a causative role of these particular mutations in glaucoma pathogenesis. However, a majority of TIGR/MYOC missense variants are present at a low frequency among glaucoma patients or control groups and have not been studied in large families. In such + To whom correspondence should be addressed. Tel: +1 650 723 3290; Fax: +1 650 723 7016; Email: vollrath@genome.stanford.edu cases, a conclusive distinction between a disease-causing mutation and a benign variant has not been possible because of the small number of normal or affected individuals identified who harbor a particular sequence change. The inability to distinguish between deleterious and benign variants not only degrades efforts to infer protein functional information from the location of mutations, it also creates a dilemma for the genetic counseling of individuals with rare TIGR/MYOC variants because it is unclear whether such individuals are at increased risk for developing POAG. An assay is needed to differentiate normal and mutant forms of TIGR/myocilin. In this report, we describe such an assay and use it to assess some of the ambiguous rare missense variants in TIGR/MYOC that have been previously classified as probable disease-causing mutations or probable benign sequence changes.
RESULTS
To study the characteristics of normal and mutant forms of TIGR/myocilin, we introduced DNA constructs encoding epitope-tagged versions of the protein (Fig. 1) into the human embryonic kidney (HEK) cell line 293T by liposome-mediated transient transfection. In the course of these studies, we noticed that mutant forms of the protein seemed to be less soluble than normal protein when extracted from cells with the non-ionic detergent Triton X-100. Triton extraction is commonly used to partition cellular proteins and many cytoskeletal proteins are relatively insoluble in Triton (31, 32) . We adapted a Triton extraction protocol used to study mutant and wild-type forms of the merlin protein (33, 34) to the study of TIGR/myocilin, in order to determine whether the apparent difference in Triton solubility of normal TIGR/myocilin and its mutated counterparts was general and reproducible.
Normal TIGR/myocilin is Triton soluble whereas mutant protein is not
The Pro370Leu mutant of TIGR/myocilin is associated with a phenotype of especially early onset POAG (average age at diagnosis~12 years), accompanied by high IOPs in affected individuals (average maximum IOP >35 mm Hg) (18, 21, 26, 35) . This aggressive glaucoma phenotype has been observed in six Caucasian families of northern European origin (12, 18, 21, 24, 26) and one Japanese family (10) , leading to the suggestion that Pro370Leu is a strong mutant allele of TIGR/MYOC (12, 21) .
We compared the Triton solubility of the Pro370Leu mutant with normal TIGR/myocilin. DNA constructs encoding FLAG epitope-tagged (36) versions of the two proteins were separately transfected into HEK cells. After 2 days, cells were extracted with a buffer containing 0.5% Triton X-100. The soluble and insoluble fractions were concentrated and equivalent amounts were analyzed by SDS-PAGE and immunoblotting.
We observed a clear difference in the behavior of normal and Pro370Leu mutant proteins; nearly all of the normal epitopetagged TIGR/myocilin is soluble, while the Pro370Leu mutant protein remains almost completely in the insoluble pellet ( Fig.  2A) . Comparable results have been obtained in more than 20 replications of this experiment and similar results were obtained when the same DNA constructs were introduced into HeLa, NIH 3T3 or COS7 cells (Fig. 2B) , demonstrating that the phenomenon is not cell-type specific. TIGR/myocilin endogenously expressed by HEK cells is soluble, like epitopetagged normal protein ( Fig. 2A) .
The difference in Triton solubility between mutant and normal protein is immediate
To assess the kinetics of insolubility, we performed Triton extraction at various times after transfection of DNA Figure 1 . TIGR/myocilin structure and DNA constructs. The primary amino acid structure of human TIGR/myocilin is depicted above with the location of various domains and putative functional or structural regions indicated. A cassette encoding 10 amino acids that included the FLAG epitope tag was inserted immediately after codon 35 of the TIGR/myocilin cDNA. Starting with this epitope-tagged normal TIGR/myocilin construct, site-directed mutagenesis was employed to make 21 separate variants in the olfactomedin-like domain (black vertical lines). constructs encoding normal or Pro370Leu mutant TIGR/ myocilin. Normal and mutant proteins were detectable by immunoblot as early as 36 and 24 h after transfection, respectively (Fig. 3A) . The difference in Triton solubility of the two types of protein at the earlier times is apparent and indistinguishable from that seen later, an indication that a high protein concentration within cells is not required for mutant insolubility. In fact, when large amounts of DNA were transfected into HEK cells to intentionally overproduce Pro370Leu protein, the proportion of soluble mutant protein increased (Fig. 3B ). In contrast, normal TIGR/myocilin remains almost completely soluble over a similar range of DNA concentrations (data not shown).
Triton insolubility is a general characteristic of mutant TIGR/myocilin proteins
To investigate whether Triton insolubility is a general property of glaucomatous forms of TIGR/myocilin, we made DNA constructs for 11 additional TIGR/MYOC mutants, all of which affect the olfactomedin-like domain of the protein. The 11 mutations were chosen because their causative role in POAG has been firmly established (Table 1) . Constructs were separately transfected into HEK cells and Triton extraction was performed for each mutant protein after 2 days (Fig. 4) . Immunoblot analysis showed that most mutant proteins behaved like Pro370Leu in that they were almost completely insoluble and two mutant proteins (Gly364Val and Asp380Ala) were substantially insoluble. When compared with the nearly complete and highly reproducible solubility of normal TIGR/ myocilin, these results indicate that Triton insolubility is a characteristic of bona fide glaucomatous mutant TIGR/ myocilin proteins.
Human→ → → →murine amino acid substitutions in the olfactomedin-like domain of human TIGR/myocilin yield Triton-soluble proteins
Murine TIGR/myocilin and its human ortholog are 81% identical (42) (43) (44) , consistent with a conservation of function between the murine and human proteins. If the insolubility that we observe is specific for glaucomatous mutant TIGR/ myocilin proteins and not simply the result of substitutions in the olfactomedin-like domain, then changing an amino acid residue in human TIGR/myocilin to that found in the murine protein should not affect the solubility of human TIGR/ myocilin. As a test of this hypothesis, we made DNA constructs encoding two human→murine substitutions in the olfactomedin-like domain of human TIGR/myocilin. One of the substitutions (Glu409Ala) results in a change in net electrostatic charge of the protein, while the other (Ala386Ser) results in a change in polarity of a residue. Of a total of 21 probable disease-causing mutations, classified on the basis of an apparent increased frequency among glaucoma patients as compared with controls, 17 resulted in a change in charge, polarity or size of a residue and were termed 'non-conservative' (13) . By this definition, both human→murine substitutions are non-conservative changes.
DNA constructs encoding the two TIGR/myocilin variants were transfected into HEK cells and Triton extraction was performed. Immunoblot analysis showed that neither of the human→murine substitutions had an effect on the solubility of otherwise normal human TIGR/myocilin; both proteins were almost completely soluble (Fig. 5) . These controls provide further evidence that Triton insolubility is a characteristic of mutant forms of TIGR/myocilin found in familial glaucoma and indicate that the Triton extraction procedure that we have developed can be used as a biochemical assay to distinguish normal and mutant forms of TIGR/myocilin found in POAG patients, normal controls and/or the general population.
Test of ambiguous variants
Seven TIGR/MYOC missense variants for which strong evidence for or against a causative role in glaucoma is not available (Table  1) were tested in the Triton extraction assay. Of the seven variants, three (Thr377Met, Arg422His and Ile499Phe) were previously described as probable disease-causing mutations, while three (Lys398Arg, Arg422Cys and Val495Ile) were thought unlikely to be pathogenic mutations. A seventh variant (Glu352Lys) has been described as a probable mutation (13) or as a probable benign sequence change (11, 12) . Results of the Triton extraction assay are consistent with previous predictions for four of the six variants (Fig. 6) . Results for two of the variants are at odds with previous predictions; Arg422Cys, a putative normal variant, behaves like a mutant, demonstrating substantial insoluble protein, while Arg422His, a putative disease-causing mutation, yields a completely soluble protein. The solubility of the Glu352Lys variant protein is indistinguishable from normal TIGR/myocilin.
DISCUSSION
More than 40 amino acid sequence variants of TIGR/myocilin have been reported (4,10-13,18,20-30 ). Most are missense variants identified in a small number of individuals and present at an overall population frequency well below 1% and most appear to be population specific (13) . It is therefore difficult to conclusively classify many of the variants as pathogenic mutations or benign sequence changes. We have shown that substantial insolubility in Triton X-100 is an attribute of mutant forms of TIGR/myocilin expressed through transfection of HEK cells; all 12 bona fide mutant proteins tested displayed substantial Triton insolubility, while normal TIGR/ myocilin and controls were soluble. These observations serve Family with 7 affecteds and 2 carriers 18 + Figure 4 . Triton insolubility of 11 familial glaucoma mutants of TIGR/myocilin. An additional 11 TIGR/myocilin mutants, for which there is strong evidence of a causative role in glaucoma (Table 1) , were tested in the Triton extraction procedure after transfection into HEK cells. The figure is a composite of four experiments. A normal control was included in each experiment. An aliquot of 0.2 µg of DNA was used for each construct and exposure times varied from 10 to~30 s.
as the basis for a general and reproducible cellular assay that distinguishes between mutant and normal forms of TIGR/ myocilin.
Comparison of assay results to prior inferences about ambiguous variants
Seven ambiguous variant proteins were tested in the assay and classified as mutant or normal. The Lys398Arg variant was found at a frequency of~1% among both glaucoma probands and control subjects and presumed to be a probable benign polymorphism (11, 13) . Our results demonstrating Tritonsoluble Lys398Arg protein confirm this conclusion. A compound variant allele of Val495Ile and Thr377Met was found in two members of a single glaucoma family (11), while Thr377Met alone was found in two other families (11, 12) , one of which was large enough to generate suggestive, but not conclusive, statistical support for a causative role in glaucoma (11) . The Val495Ile variant was presumed to be benign (11) and our assay results substantiate this conclusion as well as the conclusion that Thr377Met is a pathogenic mutation. We also tested the compound variant and found no difference in solubility between it and the Thr377Met variant (data not shown). The Ile499Phe variant has been observed in seven affected and two unaffected members of the same family (18) . One of the carriers is 6 years older than the oldest affected member. The Triton insolubility of this variant supports the conclusion that it is a glaucoma-causing mutation and suggests that the oldest carrier represents a case of reduced penetrance. Our assay results are at odds with previous predictions for two variants at the same amino acid position in TIGR/ myocilin. The Arg422His variant, previously classified as a probable disease-causing mutation (11) , behaves like the normal protein and we infer that it is a benign sequence change with no causative role in glaucoma. This variant was present in only one of 716 glaucoma probands tested and not found in a smaller number (596) of controls (11) . In light of the genetic heterogeneity of glaucoma and its relatively high population prevalence, we suppose that the POAG manifest by this individual arises from causes unrelated to the Arg422His variant. The Arg422Cys variant, described previously as unlikely to be a pathogenic mutation (11) , behaves like a mutant protein in our assay and is probably a disease-causing mutation. The mutation was identified in a single individual from the general population whose glaucoma status was not known (11) . We predict that this individual is at increased risk for developing POAG as a result of a mutation in TIGR/MYOC.
The Glu352Lys variant was previously classified as both a probable benign sequence change (11, 12) and as a probable disease-causing mutation (13) . Our results indicate that Glu352Lys is a benign sequence change. The variant was found in one of four affected members and one 48-year-old unaffected member of an African-American family with adult onset POAG (12) . Interestingly, at least three of six other glaucoma probands reported to carry the variant are also of African origin (13, 45) . It is therefore likely that this variant represents a benign change that is found predominantly among Africans (12) and that it was not detected among normal controls because of the smaller number of African controls tested (13) .
Together, our results for the seven ambiguous variants demonstrate the utility of the assay to differentiate between rare glaucoma-causing mutations and benign sequence changes. All of the variants tested fell within the C-terminal 200 amino acids of TIGR/myocilin, where~90% of putative mutations have been found. It remains to be seen whether the assay is applicable to variants outside this region.
Relationship of glaucoma phenotype to degree of Triton insolubility
Of the 12 bona fide pathogenic mutations tested, 10 displayed near complete Triton insolubility. The remaining two mutations, Gly364Val and Asp380Ala, display a degree of insolubility that is clearly distinguishable from normal protein and controls, but is not as complete as that observed for the other 10 mutations (Fig. 5) . Similar results were obtained for Thr377Met, Arg422Cys and Ile499Phe (Fig. 6) . Available descriptions of the phenotypes of family members with POAG and a mutation associated with partial solubility reveal a later mean age at diagnosis and a lower mean maximum IOP as compared with glaucoma phenotypes for some of the mutations associated with near complete insolubility ( Table 2 ). This trend is particularly striking in light of the fact that the phenotypic data were collected from a variety of Caucasian populations by research groups in a number of different countries, so environmental and genetic background effects may diminish phenotypic differences due to mutant alleles. On the other hand, there is substantial overlap in the range of these parameters in the two groups and the small number of examples of each type makes the significance of these apparent differences uncertain. A clear exception to the suggested correlation between degree of solubility and severity of glaucoma phenotype is the Gln368Stop mutation, which has been associated with a significantly later onset, lower IOP phenotype and incomplete penetrance (11, 22) . The Gln368Stop protein is completely insoluble, but it may well represent a special case because premature termination mutations can destabilize mRNA, leading to decreased production of mutant protein (46) . The milder phenotype of Gln368Stop may therefore be unrelated to the characteristics of the mutant protein.
Implications for a model of glaucoma pathogenesis
The relative Triton insolubility of mutant forms of TIGR/ myocilin may provide clues to understanding the mechanism by which mutations in the gene cause a dominant POAG phenotype. The complete insolubility of Pro370Leu mutant protein at the earliest detectable time (Fig. 3A) and the appearance of soluble mutant protein at high levels of expression (Fig. 3B) are consistent with a model of saturable binding of mutant protein to one or more cellular components. The cellular components might themselves be Triton insoluble, or Triton insolubility might result from a complex of mutant protein with otherwise soluble components. Normal TIGR/ myocilin can form dimers and, possibly, higher multimers (47,48; Z. Zhou and D. Vollrath, unpublished data), suggesting that mutant protein may interfere with normal protein through formation of heteromultimers. A fraction of normal TIGR/ myocilin may be retained in cells along with mutant protein, resulting in decreased secretion of normal protein. This model is consistent with the observation that expression of a mutant form of TIGR/myocilin in perfused human anterior segments through use of a recombinant adenovirus results in a reduction in the amount of normal, endogenous TIGR/myocilin present in the perfusate (49) . Other models of pathogenesis are also possible, such as disruption by mutant protein of the processing of normal TIGR/myocilin through binding and sequestration of another protein or cell death due to accumulation of insoluble protein complexes. Regardless of the specific model, the fact that Triton insolubility of mutant protein occurs in at least four different cell lines derived from a number of different tissues and mammalian species indicates that the insolubility is likely the result of a general cellular mechanism.
To our knowledge, the assay we have developed is the first description of a biochemical difference in the general characteristics of normal and mutant forms of TIGR/myocilin protein. The assay will be useful for classifying rare TIGR/ MYOC variants. In addition, a better understanding of the Triton insolubility phenomenon, including identification of proteins that interact with mutant and normal TIGR/myocilin, may provide insight into the molecular pathology of glaucoma.
MATERIALS AND METHODS

DNA constructs
A TIGR/MYOC cDNA was amplified by PCR from a human heart cDNA library (Clontech, Palo Alto, CA) with primers flanking the coding region for TIGR/myocilin, cloned into the vector pGEM-T (Promega, Madison, WI) and verified by sequencing. The cDNA was subcloned into the eukaryotic Figure 6 . Triton solubility of ambiguous variants of TIGR/myocilin. A total of seven TIGR/myocilin missense variants, for which strong evidence for or against a causative role in glaucoma is not available, were tested in the Triton extraction assay after transfection into HEK cells. The three variants to the left were previously described as probable mutations (see text), while the three to the right were thought to be benign sequence changes. The Glu352Lys variant has been described at different times as mutant or benign. We tested five of the ambiguous variants (Glu352Lys, Thr377Met, Lys398Arg, Arg422His and Val495Ile) in COS7 cells and obtained results similar to those shown. 
Cell culture and transient expression of TIGR/myocilin in HEK cells
Cells were maintained in Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum (Life Technologies, Gaithersburg, MD). Exponentially growing cells were seeded 24 h before transfection. DNA was transfected into cells grown in 6-well plates with Lipofectamine Plus (Life Technologies) according to the manufacturer's protocol. Briefly, DNA was diluted in 100 µl of serum-free medium and 6 µl of lipofection reagent was added and incubated at room temperature for 15 min. Then, 4 µl of reagent diluted in 100 µl of serum-free medium was added and incubated for another 15 min. The DNA-lipid complexes were added to cells which had been rinsed once with serum-free medium and incubated at 37°C and 5% CO 2 . After 3 h, medium with serum was added to bring the final concentration of serum to 10% and the medium was changed 1 day after transfection. For HEK and COS7 cells, 0.2 µg of DNA were used for transfection in each well of a 6-well plate. One microgram of DNA was used for HeLa and NIH 3T3 cells.
Triton X-100 extraction
Other than where noted, Triton extraction was performed 45 h after transfection. Transfected HEK cells in a 6-well plate were washed with Dulbecco's phosphate-buffered saline (PBS) twice, then incubated for 40 s with 300 µl of extraction buffer (50 mM MES, 3 mM EGTA, 5 mM MgCl 2 , 0.5% Triton X-100, pH 6.4). Detergent-soluble material was precipitated in 80% acetone for 4 h at -20°C and the pellet was recovered after centrifugation (14 000 r.p.m. for 30 min in an Eppendorf microfuge). One milliliter of PBS was added to the detergent-insoluble material. It was scraped off the culture well and collected by centrifugation at 14 000 r.p.m. for 10 min in an Eppendorf microfuge. Pellets containing either detergent-soluble or detergent-insoluble material were resuspended in 50 µl of Laemmli sample buffer and boiled for 10 min prior to electrophoresis.
Analysis of TIGR/myocilin by SDS-PAGE and immunoblot
HEK cell extracts were subjected to SDS-PAGE, electrophoretically transferred to NitroBind nitrocellulose membrane (MSI, Westborough, MA), blocked with 5% non-fat dry milk in TBST blocking buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween-20) for 1 h at 23°C and incubated for 1 h in blocking buffer with either an anti-FLAG monoclonal antibody M2 (Eastman Kodak, New Haven, CT) or an affinitypurified anti-TIGR polyclonal antibody (Z. Zhou and D. Vollrath, unpublished data). Unbound antibody was removed by washing three times for 10 min with blocking buffer and goat anti-mouse or goat anti-rabbit IgG horseradish peroxidase conjugate (Promega, Madison, WI), diluted to 1:10 000 in blocking buffer, was added for 1 h. The blot was subjected to two 10 min washes in blocking buffer, followed by three 10 min washes with TBST, and then treated with a chemiluminescence substrate (Pierce, Rockford, IL) and immediately exposed to ECL Hyperfilm (Amersham, Arlington Heights, IL).
